Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AB Science, Antengene, Bayer, Chemocentryx, Coya, Diurnal, Enochian, Gensight, Inotrem, Iveric, Janssen, Kintor, Prilenia, Provention, Seagen, Sigilon, Sirnaomics, Soleno, Tetra, Tevogen, Valneva.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alterola, Abti, Aridis, Astellas, Blue Water, Cellectar, Etherna, Evgen, Evrys, Excellthera, Exevir, Heat, Intocell, Legochem, Probiogen.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Carrot, Quidel, Ortho Clinical Diagnostics, Uvision360.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aditxt, Bardy Diagnostics, Dariohealth, Hillrom, Histosonics, Tada Medical.
DUBLIN – Inotrem SA has received €45 million (US$53 million) in public funding commitments to move its Trem-1 inhibitor, nangibotide, into a phase II/III trial in COVID-19 patients who are critically ill and on ventilation.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Beigene, Bluebird, Humanigen, Innovent, Lysogene.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Eurofins, Lazurite, J&J, Mission Bio, Quantumdx, Rite Aid, Sequanta Technologies.